Moderna and Merck Cancer Vaccine Breakthrough Paves Way for Thousands
A major breakthrough in cancer treatment has been announced by Moderna and Merck Co Inc. The companies reported that their personalised cancer vaccine, known as intismeran autogene, has shown success in a large-scale trial of melanoma patients.
The trial involved over 1,000 participants who had localised melanoma tumours that were removed surgically but had a high chance of reoccurring. The results showed that the treatment, which combines Moderna's vaccine with Merck's widely used immunotherapy drug pembrolizumab (Keytruda), met primary targets including reducing cancer recurrence and preventing tumors from spreading to other parts of the body.
The success of this treatment has significant implications for thousands of melanoma patients. According to Moderna, this number could reach thousands within the first few years of its release. The companies are already in talks with regulators about the treatment, and a spokesperson predicted it could be available as soon as next year.